Results 171 to 180 of about 207,794 (393)

Dyskeratosis Congenita Associated Non-Specific Interstitial Pneumonia [PDF]

Journal of Krishna Institute of Medical Sciences University, 2017
Dyskeratosis Congenita (DC) is a rare inherited disorder of ectodermal dysplasia. It consists of a classical mucocutaneous triad of abnormal skin pigmentation, nail dystrophy and leukoplakia. Pulmonary disease is seen in 10-15%.
Unnati D. Desai , Jyotsna M. Joshi
doaj  

Efectos dun programa de rehabilitación pulmonar en pacientes con fibrosis pulmonar idiopática: unha revisión bibliográfica [PDF]

, 2017
[Resumen] Objetivo. El objetivo principal de la presente revisión bibliográfica es analizar los efectos de un programa de rehabilitación pulmonar en pacientes diagnosticados de fibrosis pulmonar idiopática (FPI). Material y método.
Pérez Díaz, Andrea
core  

Practical Applications of Secondary/Extractive Electrospray Ionization (SESI): A Versatile Tool for Real‐Time Chemical Analysis

Mass Spectrometry Reviews, EarlyView.
ABSTRACT In the 1980s, researchers discovered the remarkable ability of electrospray plumes to effectively ionize gas‐phase molecules via secondary ionization. Around 20 years later—coinciding with the ambient mass spectrometry revolution—secondary electrospray ionization (SESI) and extractive electrospray ionization (EESI) coupled to mass spectrometry
Xin Luo, Huiling Wang, Xiaolan Hu, Sasho Gligorovski, Xue Li, Pablo Sinues   +5 more
wiley   +1 more source

Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1) [PDF]

, 2009
Ganesh Raghu, Talmadge E. King, Jürgen Behr, Kevin K. Brown, R M du Bois, Isabelle Leconte, Sébastiên Roux, Jeffrey J. Swigris   +7 more
openalex   +1 more source

Deep Learning Reconstruction for 129Xe Diffusion‐Weighted MRI Enables Use of Natural Abundant Xenon and Improved Image Acceleration

Magnetic Resonance in Medicine, EarlyView.
ABSTRACT Purpose (i) To assess whether 129Xe apparent diffusion coefficient (ADC) and diffusive length scale (LmD) metrics are quantitatively preserved with deep learning (DL) accelerated acquisition and reconstruction and (ii) to evaluate the feasibility of 129Xe diffusion weighted imaging with natural‐abundance xenon at increased acceleration factors.
Rajagopalan Sundaresan, Guilhem J. Collier, Neil J. Stewart, Sudhanya Chatterjee, Ramesh Venkatesan, Jan Wolber, Jim M. Wild   +6 more
wiley   +1 more source

HFE gene variants and iron-induced oxygen radical generation in idiopathic pulmonary fibrosis [PDF]

, 2014
Federica Sangiuolo, Ermanno Puxeddu, Gabriella Pezzuto, Francesco Cavalli, Giuliana Longo, Alessia Comandini, Donato Di Pierro, Marco Pallante, Gianluigi Sergiacomi, Giovanni Simonetti, Maurizio Zompatori, Augusto Orlandi, Andrea Magrini, Massimo Amicosante, Francesca Mariani, Monica Losi, Daniela Fraboni, A Bisetti, Cesare Saltini   +18 more
openalex   +1 more source

A Proteomics Resource Investigating Fibrosis: Proof‐of‐Concept for Identifying Novel Drug Candidates

PROTEOMICS, EarlyView.
ABSTRACT Fibrosis is characterised by inappropriate wound healing and the buildup of excessive fibrous connective tissue, in particular within the extracellular matrix (ECM). This can occur in multiple organs, ultimately leading to organ failure. Despite the high burden of fibrosis, treatment options only delay disease progression.
Hanne Devos, Manousos Makridakis, Rafael Stroggilos, Mayra Alejandra Jaimes Campos, Aggeliki Tserga, Marika Mokou, Maria G. Roubelakis, Jerome Zoidakis, Antonia Vlahou, Agnieszka Latosinska   +9 more
wiley   +1 more source

Clinical implication of protease-activated receptor-2 in idiopathic pulmonary fibrosis [PDF]

, 2012
Young Sik Park, Chang Min Park, Hyun Ju Lee, Jin Mo Goo, Doo Hyun Chung, Sang‐Min Lee, Jae‐Joon Yim, Young Whan Kim, Sung Koo Han, Chul‐Gyu Yoo   +9 more
openalex   +1 more source

Exposure‐Efficacy Meta‐Model of Nintedanib in Adult Patients With Chronic Fibrosing Interstitial Lung Diseases

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT The tyrosine kinase inhibitor, nintedanib, reduces the rate of decline in forced vital capacity (FVC) in a comparable manner in patients with idiopathic pulmonary fibrosis (IPF), other forms of progressive pulmonary fibrosis (PPF), and systemic sclerosis‐associated ILD (SSc‐ILD).
Sonja Hartmann, Julie Janssen, Jakob Ribbing, Susanne Stowasser, Julia Korell   +4 more
wiley   +1 more source

Population Pharmacokinetics and Exposure‐Response Model‐Based Bayesian Extrapolation of FVC‐Based Efficacy Endpoints From Adults to Pediatric Patients Receiving Nintedanib

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Nintedanib reduces the rate of decline in forced vital capacity (FVC) in adult patients with idiopathic pulmonary fibrosis (IPF), chronic progressive‐fibrosing interstitial lung diseases (ILDs) and systemic sclerosis‐associated ILD (SSc‐ILD).
Sonja Hartmann, Anna Chan Kwong, Jakob Ribbing, Martina Gahlemann, Julia Korell   +4 more
wiley   +1 more source